腾盛博药-B：截至2024年12月31日止年度之年度业绩公告及变更所得款项用途

Brii Biosciences Limited騰盛博藥生物科技有限公司2137 20241231 20241231 •202412312,413.4202312312,661.4248.09.3% •20241231141.420231231163.722.313.6%20.8 •20241231249.820231231402.7152.938.0%79.367.7 •20241231153.220231231196.543.322.0%39.7 •20241231512.420231231184.4328.0177.9%126.190.3131.8129.2 騰盛博藥2024騰盛博藥2 騰盛博藥HBV2ENSUREENRICHENHANCEHBVBRII-179HBVelebsiranHBVsiRNAtobevibartHBV騰盛博藥BRII-179HBV 202411騰盛博藥ENSURE1-3elebsiranHBVelebsiran騰盛博藥BRII-179Vir Biotechnologytobevibart202412騰盛博藥ENRICHBRII-179HBVENRICHENSURE20252026騰盛博藥 202412騰盛博藥VBIBRII-179BRII-179 騰盛博藥HBVelebsirantobevibartBRII-179(CDE)20246Vir BiotechnologyFDAelebsirantobevibartVir Biotechnology202411EMA202412Vir BiotechnologyFDAEMA HBV騰盛博藥HIVMDR/XDR202410騰盛博藥MDR/XDRBRII-693CDEIND1PK 2024騰盛博藥騰盛博藥 123120242023 292,503415,473 77,421125,869 1017,971– 23,124– 2,606,0803,072,382 2,606,0803,072,382 202412 31 1. 騰盛博藥20171282021713PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands173 2. 202411 161177 97397310281113212184 1220251132026114202711 18 1811187733 1820271118 3. 20241231257,325,0002023273,029,000179,710,0002023191,233,000489,000202375,785,00077,126,00020236,011,000 20231231 4. 16.2202350.02024123116.9202350.6 5. 123120242023 6. Brii Biosciences, Inc.21%2.5%9.9% Brii Biosciences Pty Ltd.25% 25% 7. 123120242023 202320241231 202320241231 8. 202320241231 30 0303160619090 123120242023 17,971– 123120242023 17,971– HBVHBVHBVENSUREelebsiranPEG-IFNαBRII-179ENRICHBRII-179HBVelebsiranPEG-IFNαENHANCEBRII-179elebsiranPEG-IFNα HBVBRII-179elebsirantobevibartCDEHBV20252026 HBsAg2024(i)HBV(BRII-179)HBVHBsAg(ii)PEG-IFNαPEG-IFNαsiRNAHBsAgHBV 20242,413.4HBV HBVHBV (1)2騰盛博藥 •ENSUREElebsiran + PEG-IFNα vs PEG-IFNα•ENRICHBRII-179elebsiran + PEG-IFNα•ENHANCEBRII-179 + elebsiran + PEG-IFNα (2)ElebsiranBRII-835VIR-2218(3)TobevibartBRII-877VIR-34342Vir Biotechnology(4)EpetraboroleBRII-658AN2(5) HBV elebsiranBRII-179siRNAPEG-IFNαHBV2024 AASLD The Liver Meeting®ENSUREEOTPEG-IFNαsiRNAPEG-IFNαHBsAg20242HBVHBVHBsAg ENSUREelebsiranPEG-IFNαPEG-IFNαENRICHBRII-179HBVENHANCEBRII-179BRII-835PEG-IFNα20252026HBV HBVMDR/XDRHIV HBVHBVHBV87 BRII-179 BRII-179HBVPre-S1Pre-S2S HBVBT202412VBIBRII-179 •ENSURE4BRII-1794202532025APASLENRICHBRII-179HBV202411 •202462024EASL™2BRII-179elebsiranHBVBTPEG-IFNαBRII-179HBsAgBRII-179HBV ElebsiranTobevibart ElebsiranHBVsiRNAHBVRNAHBVHDVsiRNA2020VirBiotechonologyelebsiran TobevibartHBVHBVHDVTobevibartFcHBsAgXencorXtend™2022Vir Biotechonologytobevibart •20252026BRII-179elebsiranPEG-IFNαENSUREENRICHENHANCE •20251ENHANCEENHANCE2bBRII-179elebsiranPEG-IFNαPEG-IFNαHBV •202411AASLD The Liver Meeting®2ENSURE48EOTPEG-IFNαelebsiranPEG-IFNαHBVENSUREPEG-IFNαsiRNA (elebsiran)PEG-IFNαelebsiranHBV2025ENSURE •Vir Biotechnology202411AASLD TheLiverMeeting®2MARCHPEG-IFNαtobevibartelebsiranHBVSOLSTICEtobevibartelebsiranCHDVir Biotechnology202533(ECLIPSE)tobevibartelebsiranCHD •Tobevibart1 •2024tobevibartelebsiranCHDVir BiotechnologyFDAtobevibartelebsiranCHDEMA HBVMDR/XDRHIV BRII-693MDR/XDRBRII-693BRII-693MDR/XDRBRII-693 FDABRII-693 QIDPFDA •202410騰盛博藥CDEINDBRII-6931PK1202412Antimicrobial Agents and Chemotherapy3 HIV BRII-753NRTTIEFdANCEBRII-753HIV BRII-732NCEEFdAHIVEFdANRTTIHIVBRII-7321HIV EpetraboroleBRII-658LeuRSepetraborole •AN2epetraborole 2/32AN22025332AN2FDA •20241260202462510%4,433,0005.3 •202412VBI18BRII-179VBIBRII-179PreHevbriTM2024214BRII-179BRII-179 Zhi HongDavid MargolisBrian A. JohnsEllee de Groot 20241231249.8 HBVHBVHBV HBV 20241231 20231231163.722.320241231141.420.85.4 2. 20231231252.4450.120241231197.7 3. 2023123119.611.7202412317.9202488 20231231402.7152.920241231249.8HBV79.367.7 5. 20231231196.543.320241231153.220231231126.539.72024123186.8 6. 20241231202312312,661.42,413.4 7. 1,32629,756 (248,521)(372,949) 8. 2024123120231231 (1) (2)100% 9. 2024123118.0 20241231 202412311610.0 10. 2024123120241231 11. 2024123120231231 12. 2024123148.1%35.1%16.6%0.2% 13. 202412319820241231 2024HBV 202412311942023123130236% 14. 202171326.142023324 202412311,082.3 20241231 2027 a)HBVHBVHIVMDR/XDRCNS2341.1 b)202412VBI Vaccines, Inc.VBIK2 VBI Equity Trust, LLCK2 HealthVentures LLCBRII-179BRII-179BRII-179BRII-179VBI1.2BRII-179 20241231 202561720256122025617202561116172025617 C1C.2.1 C.2.1Zhi HongHongHongHongHong C3 20241231 Grace Hui TangGrace Hui Tang2024123120241231 • •202412312025321•• PFIC 2024123120241231PFICPFIC 20241231PFICPFIC2024322 (www.hkexnews.hk)(www.briibio.com)20241231 騰盛博藥騰盛博藥 EASLEFdANRTTIHIVEMAENHANCEH B VB R I I - 1 7 9elebsiranPEG-IFNαENSUREHBVelebsiranPEG-IFNαENRICHBRII-179elebsiranPEG-IFNαHBVEOTHBsAgHBVHDVHIV INDMACMARCHsiRNAC3MDR/XDRNCENDANRTTINTMPEG-IFNααPK2021630QIDP20241231RNA 0.00001 siRNAR N AR N ARNARNA Vir Biotechnology, Inc.VIR 騰盛博藥生物科技有限公司Zhi Hong 2025321 Zhi HongMartin J Murphy JrGrace Hui TangGregg Huber Alton